Last verified on July 21, 2017
NRC Frequently Asked Questions
On this page
- Non-Authorized User Duties
- Radioisotope Safety Exam (RISE) FAQs
- What is the nature of the exam?
- How long is the exam?
- What What material does it cover?
- Does the ABR provide guidelines to facilitate preparation?
- If I choose to defer taking the exam, what options/dates will be available to me later?
- What is the fee to take the exam?
- Where can I take the exam?
- What benefit/rights does eligibility give me?
- When will I receive my exam results?
Non-Authorized User Duties
If a radiologist is not an Authorized User (AU) on an NRC license at an institution, what duties may he or she perform in the nuclear medicine laboratory of that facility?The NRC recognizes that it is frequently necessary for an Authorized User (AU) to delegate to other individuals the specific tasks associated with preparing and administering by-product material (radiopharmaceuticals) for medical uses in patients (10 CFR 35.27). These individuals include technologists and other physicians who may not be AUs. If the policies and procedures of the institution holding an NRC radioactive materials license allow, the NRC regulations (10 CFR 35, subparts D* & E**) permit delegation of these duties if the individuals performing the duties are properly instructed and supervised. The supervising AU does not need to be physically present for delegated use of by-product material under subparts D & E. Further, there is no NRC requirement that diagnostic studies performed using by-product material have to be interpreted by an AU. Thus, the NRC regulations do not restrict who can read and interpret diagnostic scans or the results of therapeutic procedures (i.e., radiologists who are not AUs may interpret such studies). However, it is strongly recommended that those radiologists practicing in NRC Agreement States consult the appropriate state regulatory agency to ensure that the state regulations allow for this delegation. According to NRC regulations, only an AU can sign a written directive, including those necessary for therapeutic procedures involving unsealed by-product material (e.g., treatment of hyperthyroidism, ablation of residual function thyroid tissue, or treatment of functioning thyroid metastases using 131I). However, administration of the therapeutic unsealed by-product dose specified in the written directive may be delegated, if the individuals performing the administration are properly instructed in the written directive procedures and supervised accordingly. *Subpart D- Unsealed By-product Material – Written Directive Not Required
- 35.100 – Use of unsealed by-product material for uptake, dilution, and excretion studies for which a written directive is not required
- 35.200 – Use of unsealed by-product material for imaging and localization studies for which a written directive is not required